Oscar Health's net risk adjustment payable stood at $2.99 billion at September 30, 2026, against $1.68 billion a year earlier, according to the third-quarter release the company filed on November 5. Membership was 2.69 million against 2.12 million, so the payable grew 78% while the book grew 27%. Over the same quarter the medical loss ratio improved to 84.0% from 88.5%.

Favorable prior period development was $42 million in the quarter against $84 million a year earlier. Revenue "included a $250 million benefit from updated risk adjustment estimates" (Oscar Health Form 8-K, November 5, 2026). Earnings from operations were $178.0 million against a $129.3 million loss. Full-year operating earnings guidance rose to $850 million to $950 million from $600 million to $800 million, the third raise this year.

Four months earlier CMS had published its summary report on 2025 benefit year transfers, which put individual-market risk adjustment at 11.0% of premiums nationally. Oscar's transfer ran 17.2% of direct policy premium for the nine months, per the 10-Q.

Key Takeaways

  • Oscar's medical loss ratio improved on pricing and a risk adjustment update: 84.0% against 88.5%, with favorable prior period development halving to $42 million.
  • The net risk adjustment payable grew faster than the book: $2.99 billion against $1.68 billion, or $1,112 per member against $793.
  • As a share of direct premium the transfer fell: 11.8% in the quarter against 20.0%, after a $250 million reduction to the accrual.
  • Guidance moved up for the third time, to operating earnings of $850 million to $950 million, which implies a fourth-quarter operating loss.
  • CMS will not settle the 2026 benefit year until its transfer report due by June 30, 2027, so the balance stays an estimate until then.

What the release reports

Total revenue was $5.14 billion against $2.99 billion, and net premium $5.04 billion against $2.92 billion. Medical expenses of $4.23 billion against $2.59 billion produced the 84.0% ratio. Oscar attributed the improvement "primarily" to its pricing strategy; the nine-month ratio was 78.1% against 84.8%.

SG&A expense ran 14.0% of revenue against 17.5%, which the release attributes first to "lower risk adjustment as a percentage of premium" and then to fixed-cost leverage. Net income attributable to Oscar was $167.3 million against a $137.5 million loss. Adjusted EBITDA was $206.9 million against a $101.5 million loss.

MetricQ3 2026Q3 2025
Medical loss ratio84.0%88.5%
Favorable prior period development$42M$84M
SG&A expense ratio14.0%17.5%
Earnings (loss) from operations$178.0M($129.3M)
Effectuated members, September 302,691,8852,116,904
Net risk adjustment payable, September 30$2,994.6M$1,678.7M
Risk adjustment transfers, share of direct policy premium11.8%20.0%

Full-year guidance now reads revenue of $19.0 billion to $19.3 billion, from $18.7 billion to $19.0 billion. MLR guidance moved to 80.5% to 81.5% from 81.0% to 82.0%, and the SG&A ratio to 15.1% to 15.6%. "Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time," chief executive Mark Bertolini said in the release.

Nine-month prior period development was larger than the quarter suggests. Oscar's benefits payable rollforward in the 10-Q shows $237.4 million of favorable prior-year incurred against an opening net balance of $1.43 billion, or 16.6%. A year earlier the figure was $207.4 million. A seven-carrier comparison of reserve releases published here in October had Oscar at the top of the range at 13.6% through the first half.

The risk adjustment table, per member and per premium dollar

Oscar's risk adjustment table shows a gross payable of $3,125.4 million against a receivable of $130.8 million. Net, $2,994.6 million works out to $1,112 per effectuated member, against $793 a year earlier, a 40% increase per head while the book grew 27%.

Premium explains most of that. Direct policy premium for the quarter was $5.72 billion against $3.65 billion, up 57%. Against it, the 10-Q's premium note puts the quarter's risk adjustment transfer at $677.3 million against $727.5 million: 11.8% of direct policy premium against 20.0% a year earlier. For nine months the share was 17.2% against 17.1%.

Without the $250 million update, the quarter's share would have been higher. Nine-month transfers would have been about $3.24 billion, or 18.6% of direct policy premium, and third-quarter net premium $4.79 billion. On that premium the quarter's $4.23 billion of medical expense produces an MLR of 88.3%, within 0.2 points of the year-earlier 88.5%. CFO Scott Blackley told analysts the comparison overstates the effect: "all of that doesn't fall to the bottom line. It comes with claims" (Oscar Health Q3 2026 earnings call, November 5, 2026).

Blackley put the full-year transfer at 17% to 18% of premiums and said "we continue to take a cautious approach to our risk adjustment reserves." Final CMS reporting "may be up to twelve months in arrears," the 10-Q says. Each 1% of the gross payable is $31 million, which at the guidance midpoint moves full-year MLR by about 0.13 points.

Last year's true-up ran the other way. Its prior-years line shows a $58.4 million favorable adjustment in the first nine months of 2026, against a $76.0 million unfavorable one in the same period of 2025. Settling the 2025 benefit year cost Oscar $2.53 billion of payments in 2026, against $1.61 billion a year earlier. Centene's marketplace book shrank 41% as its position in the same 2025 settlement turned favorable; Oscar sits on the paying side of that transfer.

CMS's 2025 report places that position in the market. Issuers in the lowest quartile of claims costs "were assessed an average risk adjustment charge of approximately 13.2 percent of total collected premiums" (CMS, June 30, 2026). Issuers in the highest quartile received 15.5%. Oscar's 17% full-year charge sits beyond the low-claims quartile average, which is where a book priced below the state average risk score lands.

The fourth quarter the guidance implies

Nine-month earnings from operations were $1.27 billion. Full-year guidance of $850 million to $950 million therefore implies a fourth-quarter operating loss of $321 million to $421 million. Earnings Whispers noted the day of the release that the raise's $200 million midpoint is smaller than the $250 million update.

Nine-month revenue was $14.67 billion, so the revenue guidance leaves $4.3 billion to $4.6 billion for the fourth quarter, with premium a little under that. A full-year MLR of 80.5% to 81.5% on that base requires a fourth-quarter ratio of roughly 89% to 92%, about 90% at the midpoint. Asked about it on the call, Blackley put the implied figure "in the range of let's call it low 90s," citing members reaching their out-of-pocket maximums. Bertolini called it "a normal seasonal uptick."

Membership is already moving: 2.69 million at September 30 is about 300,000 below the roughly 3.0 million the company reported at June 30. Blackley attributed the decline to "disenrollments from CMS's industry-wide eligibility review," with "a small number of additional disenrollments" expected in the fourth quarter. That review is the one that cut subsidies for 189,000 enrollees after 2027 rates were locked.

For 2027, Bertolini said Oscar filed "a weighted average rate increase of approximately 14%," built from high-single-digit trend, a market morbidity load and "a little bit of margin expansion." That matches the 14.4% enrollment-weighted rate change on renewing individual plans in the CMS Rate Review file. Blackley expects the exchange population to be "flat to year-end 26." He also said the 17% to 18% transfer "is specific to the risk of the book" and should not be carried into 2027.

Next year's transfer formula changes too. CMS's 2027 payment notice recalibrates the HHS models on 2021 to 2023 EDGE data and sets the user fee at $0.18 per member per month (CMS, May 15, 2026). It also requires federal-platform exchanges to verify at least 75% of special enrollment period applications before coverage starts. An earlier note here on the recalibration set out how the coefficient shift lands on filed rates.

Oscar enters open enrollment with a footprint 24% larger, adding South Carolina for a 21-state market of about 10 million consumers, Fierce Healthcare reported. Oscar's 2026 transfer is settled in the CMS summary report due by June 30, 2027; the company reports fourth-quarter results in February.